News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Impax Pharmaceuticals Release: Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference



4/18/2012 9:57:16 AM

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28. IPX066 is an investigational, patented extended release capsule formulation of carbidopa-levodopa (CD-LD) intended for the treatment of idiopathic Parkinson’s disease. IPX066 is being developed in collaboration with GlaxoSmithKline (GSK) for territories countries outside the U.S. and Taiwan.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES